From: Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
# | Reference: first author (journal, year) | Effector cell | Vehicle | Target | generation | Activation signal | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
retro | lenti | mRNA | plasmid | transposon | 1 | 2 | 3 | |||||
1 | Imai (Blood 2005) | PB-NK | x |  |  |  |  | CD19 | x | x |  | DAP10/CD137-CD3ζ/CD3ζ |
2 | Altvater (Clin Cancer Res 2009) | PB-NK | x |  |  |  |  | CD19, GD2 | x | x |  | CD3ζ/2B4/2B4-CD3ζ |
3 | Li (Cancer Gene Therapy 2010) | PB-NK |  |  | x |  |  | CD19 |  | x |  | CD137-CD3ζ |
4 | Shimasaki (Cytotherapy 2012) | PB-NK |  |  | x |  |  | CD19 |  | x |  | CD137-CD3ζ |
5 | Boissel (Leukemia Lymphoma 2012) | PB-NK/CB-NK |  | x | x |  |  | GFP, CD19, CD20 | x |  |  | CD3ζ |
6 | De Oliveira (Hum Gene Ther 2013) | HSC |  | 2 |  |  |  | CD19 | x | x |  | CD3ζ/CD28-CD3ζ |
7 | Chu (Cancer Immunol Res 2015) | PB-NK |  |  | x |  |  | CD20 |  | x |  | CD137-CD3ζ |
8 | Suerth (J Mol Med 2016) | PB-NK + NKL | a/g | 3 |  |  |  | CD19 |  |  | x | CD28-CD137-CD3ζ |
9 | Oelsner (Int J Cancer 2016) | CIK |  | 2 |  |  |  | CD19 | x | x |  | CD28-CD3ζ/CD3ζ |
10 | Chu (OncoImmunol 2017) | PB-NK |  |  | x |  |  | CD20 |  | x |  | CD137-CD3ζ |
11 | Kailayangiri (OncoImmunol 2017) | PB-NK | x |  |  |  |  | GD2 |  | x | x | CD137-CD3ζ/t2B4-CD3ζ/CD137-t2B4-CD3ζ/t2B4-CD137-CD3ζ |
12 | Kloess (Hum Gene Ther 2017) | PB-NK | a |  |  |  |  | CD123 |  |  | x | CD28-CD137-CD3ζ |
13 | Liu (Leukemia 2018) | CB-NK | x |  |  |  |  | CD19 |  | x |  | CD28-CD3ζ |
14 | Oei (Cancer Immunol Res 2018) | PB-NK |  |  | x |  |  | CD19 |  | x | x | CD28-OX40-CD3ζ/OX40-CD3ζ/CD28-CD3ζ/CD137-CD3ζ |
15 | Yu (Mol Ther 2018) | PB-NK |  | 2 |  |  |  | GPC3 |  | x |  | CD28-CD3ζ |
16 | Li (Cell Stem Cell 2018) | iPSC/NK-92 |  |  |  |  | x | Mesothelin | x | x | x | 2B4-CD3ζ/CD28-CD137-CD3ζ/DAP10-CD3ζ/CD137-CD3ζ/2B4-DAP12-CD3ζ/2B4-DAP10-CD3ζ/CD137-2B4-CD3ζ/CD3ζ |
17 | Kloess (Hum Gene Ther 2019) | PB-NK/NK-92 | a |  |  |  |  | CD123 |  |  | x | CD28-CD137-CD3ζ |
18 | Oberschmidt (Hum Gene Ther Meth 2019) | PB-NK | a |  |  |  |  | CD123 |  |  | x | CD28-CD137-CD3ζ |
19 | Colamartino (Front Immunol 2019) | PB-NK |  | 2 |  |  |  | CD19, CD22 |  |  | x | CD28-CD137-CD3ζ |
20 | Ingegnere (Front Immunol 2019) | PB-NK/NK-92 |  |  |  | x |  | CD19 | x | x |  | CD3ζ/CD137-CD3ζ |
21 | Herrera (Sci Rep 2019) | CB-NK/PB-NK |  | 3 |  |  |  | CD19 |  | x |  | CD137-CD3ζ |
22 | Bari (Front Immunol 2019) | PB-NK |  | 3 |  |  |  | CD19 |  | x |  | CD137-CD3ζ |
23 | Wang (Blood Advance 2020) | PB-NK | x |  |  |  |  | BCMA, CD123 | x |  |  | CD3ζ |
24 | Liu (NEJM 2020) | CB-NK | x |  |  |  |  | CD19 |  | x |  | CD28-CD3ζ |
25 | Muller (Front Immunol 2020) | PB-NK | a | 3 |  |  |  | CD19 |  | x |  | CD28-CD3ζ |
26 | Quintarelli (Leukemia 2020) | PB-NK | x |  |  |  |  | CD19 |  | x |  | CD137-CD3ζ |
27 | Ueda (Cancer Sci 2020) | iPSC |  | x |  |  |  | GPC3 |  |  | x | CD28-CD137-CD3ζ |
28 | Liu (Cell Proliferation 2020) | PB-NK |  | 2 |  |  |  | EGFR |  | x |  | CD137-CD3ζ |
29 | Gang (Blood 2020) | PB-NK |  | 3 |  |  |  | CD19 |  | x |  | CD137-CD3ζ |
30 | Yang (Mol Ther Methods Clin Dev 2020) | PB-NK | x |  |  |  |  | CD19 |  | x |  | CD137-CD3ζ |
31 | Wilk (Blood Advances 2020) | PB-NK |  |  | x |  |  | CD19 | – | – |  |  |
32 | Daher (Blood 2020) | CB-NK | x |  |  |  |  | CD19 |  | x |  | CD28-CD3ζ |
33 | Jamali (Front Immunol 2020) | PB-NK/NK-92/NKL |  | 3 |  |  |  | CD19 |  | x |  | CD137-CD3ζ |
34 | Gurney (Haematologica 2020) | PB-NK |  |  | x |  |  | CD38 |  | x |  | CD28-CD3ζ |
35 | Tseng (Nat Commun 2020) | NK-92MI, PB-NK | x | x |  |  |  | CD147, GPC3 |  |  | x | CD28-CD137-CD3ζ |